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Metabolic acidosis is a common complication of chronic kidney disease. Accumulating evidence identifies acidosis
not only as a consequence of, but as a contributor to, kidney disease progression. Several mechanistic pathways
have been identified in this regard. The dietary acid load, even in the absence of overt acidosis, may have
deleterious effects. Several small trials now suggest that the treatment of acidosis with oral alkali can slow the
progression of kidney disease.
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Metabolic acidosis is a common complication of chronic
kidney disease (CKD). Based on a cross-sectional analysis
of the National Health and Nutrition Examination Survey,
an estimated 26 million adults in the United States have
CKD, and approximately 700,000 individuals have an esti-
mated glomerular filtration rate (eGFR) less than 30 mL/
min/1.73 m2 [1]. As 30-50% of those with eGFR <30 mL/
min/1.73 m2 have metabolic acidosis [2-4], approximately
200,000 to 350,000 individuals with CKD stage 4 and 5
have chronic metabolic acidosis in the United States.
Chronic metabolic acidosis may have various adverse ef-
fects in patients with CKD, including altered skeletal me-
tabolism [5], insulin resistance [6], protein-energy wasting
[7-9], and accelerated progression of kidney disease. In epi-
demiologic studies, low serum bicarbonate levels have been
associated with high mortality (Table 1). In a study of 1,240
male patients with non-dialysis dependent CKD, the lowest
mortality was observed among those with baseline serum
bicarbonate levels of 26–29 mEq/L, whereas patients with
levels <22 mEq/L had a 43% higher risk of mortality [10].
Using data from the African American Study of Kidney
Disease and Hypertension (AASK) trial, Raphael et al.
showed that higher bicarbonate levels within the range of
20 to 30 mEq/L were associated with reduced risk of the* Correspondence: matthew.abramowitz@einstein.yu.edu
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article, unless otherwise stated.clinical composite outcome of death, dialysis or worsening
renal function [11]. This review focuses specifically on the
effect of metabolic acidosis on the progression of kidney
disease.Pathophysiology leading to acidosis in CKD
Under normal conditions, the extracellular H+ concentra-
tion is tightly regulated and varies little from the normal
value of approximately 40 nanomol/L. Regulation of acid–
base homeostasis involves three basic steps: chemical buff-
ering by extracellular and intracellular buffers, alteration
of alveolar ventilation, and changes in renal H+ excretion
[17]. The kidneys regulate H+ excretion by reabsorbing fil-
tered HCO3
− and generating new HCO3
− in response to
various stimuli. Secreted H+ combine with urinary buffers
such as HPO4
2− and ammonia. In CKD the reduction in
functioning nephrons causes defects in renal excretion of
acid, mainly in the form of ammonium [18]. A fraction of
patients may have inappropriate bicarbonate wasting in
the urine [19].
The acidosis in CKD usually remains relatively stable. In
uncomplicated acidosis, the serum bicarbonate levels typic-
ally are >12 mEq/L and blood pH is >7.2 [19,20]. There are
two general possibilities for this stabilization of serum
bicarbonate levels. One is that after an initial period of
acid retention, the excretion and production of acid
equalize. The other possibility is that acidosis evokes
extrarenal mechanisms that dispose of the endogenous
acid not excreted in the urine. The major source of suchd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Observational studies of serum bicarbonate and long-term outcomes in persons without end-stage renal disease






the Bronx, NY; 9%
with eGFR < 60
mL/min/1.73 m2
Kidney disease progression, defined
as 50% decrease in eGFR or
eGFR < 15 mL/min/1.73 m2
HR 1.54 (95% CI 1.13-2.09) for progression,














from the MDRD study
(1) ESRD (need for dialysis or
transplantation); (2) all-cause mortality;
(3) composite of 1 and 2
HR 1.05 (0.87-1.28), 0.99 (0.75-1.13), 1.04
(0.87-1.24) for need for kidney failure,
all-cause mortality, and composite outcome,
respectively, for serum bicarbonate 11–20
compared with 26–40 mEq/L
No • Well-characterized
cohort








Composite outcome of death, ESRD
(dialysis or transplantation), or GFR
event (defined as a GFR reduction by
50% or by 25 ml/min/1.73 m2 from
baseline)
HR 0.960 (0.924-0.998) for composite










of GFR and proteinuria
Kovesdy et al.
2009 [10]
1,240 adults at a
Veterans Affairs
Medical Center; 87%
with CKD stages 3
and 4
(1) All-cause mortality; (2) composite
of predialysis mortality and initiation of
dialysis
U-shaped association; HR for mortality 1.43
(1.10-1.87) for serum bicarbonate <22
compared with 26–29 mEq/L; similar results for
composite outcome
No • Adjustment for
time-varying serum
bicarbonate levels




et al. 2011 [13]
41,749 outpatients
with eGFR < 60
mL/min/1.73 m2
in Cleveland, OH
All-cause mortality U-shaped association; HR 1.23 (1.16-1.31)
for bicarbonate <23 compared with
23–32 mEq/L; HR 1.59 (1.49-1.69) for
reaching bicarbonate <23 mEq/L
No • Examination of
temporal change in
serum bicarbonate
• Data derived from
clinical and administrative
dataset




from the CRIC study
(1) Renal outcome, defined as 50%
decrease in eGFR or ESRD (dialysis or
transplantation); (2) atherosclerotic events;
(3) CHF events;
(4) all-cause mortality
Per mEq/L higher serum bicarbonate, HR 0.97
(0.94-0.99) for renal outcome; 0.99 (0.95-1.03)
for atherosclerotic event; 1.14 (1.03-1.26) for










old with eGFR <
60 mL/min/1.73 m2
Kidney disease progression, defined
as 25% decrease in eGFR or initiation
of dialysis
HR 0.791 (0.684-0.914) for progression,
per mEq/L higher serum bicarbonate
No • Focus on elderly
cohort
• Single measure of serum
bicarbonate





All-cause mortality HR 1.75 (1.12-2.74), 1.56 (0.78-3.09), and
2.56 (1.49-4.38) for total population, non-CKD,
and CKD subgroups, respectively, for serum
bicarbonate <22 mEq/L compared with
26–30 mEq/L
No • Nationally representative
cohort
• Single measure of serum
bicarbonate
• Compared CKD and
non-CKD subgroups
Abbreviations: HR, hazard ratio; CI, confidence interval; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; AASK, African American Study of Kidney Disease and Hypertension; ESRD, end-stage
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conducted balance studies in CKD patients with acid-
osis found a positive acid balance of approximately 10–
20 mEq per day and negative calcium balance that im-
proved with correction of acidosis [21,22]. However, the
degree of acid retention has been debated, with the sug-
gestion that these findings resulted from systematic
measurement error [23]. While the magnitude of acid
retention may be less than reported, it seems likely that
acid production does exceed excretion in the setting of
chronic renal acidosis [24].
The acidosis in mild to moderate CKD is predomin-
antly hyperchloremic, with an increased anion gap ob-
served variably and generally only with advanced CKD
[25-27]. However, accounting for changes in serum albu-
min and other electrolytes in the anion gap calculation
reveals a slightly more nuanced view. This maneuver re-
veals minor elevations in the anion gap, which are asso-
ciated with decrements in serum bicarbonate, even in
the CKD stage 2 eGFR range [28]. Although small, these
differences in anion gap are independently associated
with mortality [28]. Thus, there may be low-level accu-
mulation of organic solutes even when the GFR is rela-
tively preserved that partially accounts for changes in
the serum bicarbonate level.
Metabolic acidosis and progression of kidney disease
Epidemiologic studies have demonstrated that lower serum
bicarbonate is associated with an increased risk of kidney
disease progression (Table 1). In a single center retrospect-
ive cohort study involving patients with and without kidney
disease, the risk of CKD progression was 54% (95% confi-
dence interval (CI) 13-109%) higher for patients with bicar-
bonate levels <22 mEq/L compared with bicarbonate levels
of 25 to 26 mEq/L [4]. Among 1,781 participants with CKD
stages 2–4 from the Modification of Diet in Renal Disease
Study, compared with serum bicarbonate levels ≥26 mEq/
L, levels ≤20 mEq/L were associated with a higher risk of
kidney failure (hazard ratio (HR) 2.22 (95% CI, 1.83-2.68))
while adjusting for demographic and cardiovascular disease
factors, serum albumin, proteinuria, and cause of kidney
disease [12]. However, the association was substantially at-
tenuated and non-significant after adjustment for GFR,
measured using iothalamate clearance (HR 1.05 (95% CI,
0.87-1.28)). The implication was that lower serum bicar-
bonate was a marker for more advanced kidney disease,
and that analyses adjusting for estimated GFR were limited
by residual confounding. However, Raphael et al. performed
a similar analysis using data from 1,094 African American
participants of the AASK trial with GFR measured by
iothalamate clearance [11]. After controlling for mea-
sured GFR, higher serum bicarbonate in the 20 to
30 mEq/L range was associated with a lower risk of dia-
lysis or worsening kidney function (HR 0.932 (95% CI,0.881-0.986) per 1 mEq/L serum bicarbonate). Most re-
cently, in 3,939 participants with CKD stages 2–4 in the
Chronic Renal Insufficiency Cohort, every 1 mEq/L
higher serum bicarbonate level was associated with a 3%
(95% CI, 1-6%) lower risk of developing end-stage renal
disease or a 50% decline in eGFR during follow-up [14].
Several factors have been implicated in the effect of
metabolic acidosis on the progression of kidney disease.
These include ammonia-induced complement activation
and increased production of endothelin and aldosterone
(Figure 1). Although total ammonium excretion decreases
with progressive CKD, ammonia generation per nephron
actually increases [29]. This adaptive response may be
deleterious for the surviving nephrons [30]. Nath et al. ex-
amined the role of ammonia in the pathogenesis of tubulo-
interstitial injury using the rat remnant kidney model [31].
Chronic sodium bicarbonate supplementation lowered
renal vein total ammonia concentrations, reduced tubular
deposition of complement components C3 and C5b-9, and
ameliorated structural and functional evidence of tubulo-
interstitial damage. The authors proposed that ammonia,
as a nitrogen nucleophile, reacted biochemically with C3 to
trigger the alternative complement pathway. Therefore, the
compensatory increase in single-nephron ammoniagenesis
observed in CKD could further instigate progressive kidney
injury.
Acidosis has been shown to increase endothelin (ET)-
mediated tubulo-interstitial injury as well. ET is an
endothelial cell-derived peptide with 3 mammalian iso-
forms: ET-1, ET-2, and ET-3. The kidneys produce ET-1
in relatively high amounts and contain abundant ET re-
ceptors, particularly in the vasculature and the medulla
[32]. In vitro evidence has demonstrated that ET-1 pro-
motes the synthesis of fibronectin and collagen [33].
Several in vivo studies have correlated renal ET-1 gene
expression and urinary excretion with the degree of pro-
teinuria and glomerular and tubulo-interstitial damage
[34]. ET regulates multiple renal functional parameters,
one of which is acid–base handling. Specifically, ET-1
mediates increased renal acid excretion in response to
a systemic acid challenge. Rats given a dietary acid load
as (NH4)2SO4 increased ET-1 addition to renal inters-
titial fluid, and pharmacological inhibition of ET re-
ceptors using bosentan blunted distal tubule acidification
[35]. Using a remnant kidney model, Wesson and
colleagues demonstrated that dietary protein-induced
tubulo-interstitial injury and GFR decline were mediated
by ET, and that alkali supplementation prevented these ef-
fects [36,37].
Excess aldosterone could also mediate the decline in
GFR caused by acidosis, via its hemodynamic effects and
its pro-fibrotic actions [38]. Hyperaldosteronism in the
setting of reduced nephron mass contributes to hyperten-
sion, proteinuria and glomerulosclerosis in the remnant
Figure 1 Pathogenesis of kidney disease progression due to chronic metabolic acidosis. Metabolic acidosis and/or a high dietary acid load
may contribute to progressive kidney disease through multiple mechanisms, including increased ammonia generation per nephron leading to
activation of the alternative complement pathway and increased endothelin-1 and aldosterone levels in the kidney. Each of these factors may
cause tubule-interstitial injury leading to a decline in kidney function. Hyperaldosteronism could also accelerate glomerulosclerosis, although
glomerular injury due to metabolic acidosis has not been reported in animal models.
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high salt diet produced hypertension and severe glomerular
and tubulo-interstitial injury in non-nephrectomized rats
[41,42]. Schambelan et al. examined the effect of chronic
metabolic acidosis on adrenocortical hormone production
by administering NH4Cl for 5 days to four normal subjects,
and found that chronic metabolic acidosis induced a
sustained stimulation of aldosterone secretion [43]. Aldos-
terone mediates increased distal nephron acidification
in the setting of metabolic acidosis, and prevention of
kidney disease with alkali in the rat remnant kidney model
was associated with reduced aldosterone production in
kidney cortex [44,45].
More recently, the effect of acidosis on kidney injury
has been explored using gene expression analyses. Raj
et al. examined the effect of exposure of Madin-Darby
canine kidney cells (an immortalized cell line derived
from the dog distal renal tubule) to medium with pH 7.4
and 7.0 for 24 hours, and found that acid stress upre-
gulated the expression of genes that might participate
in the pro-inflammatory process leading to glomerulo-
sclerosis and fibrosis [46].
Dietary acid, acid retention and progression of kidney
disease
The net dietary acid load is determined by the balance
of acid-forming and base-forming precursors in the diet.
Common foods that provide a high dietary acid load in-
clude cheese, meat, eggs and grains, whereas fruits and
vegetables are rich in alkali precursors [47,48]. Generally
speaking, diets high in animal protein produce high
levels of net endogenous acid production (NEAP),
whereas vegan and vegetarian diets result in low, or
even negative, NEAP. Low NEAP can be achieved even
while preserving the proportion of energy derived from
dietary protein. This was demonstrated in the Dietary
Approaches to Stop Hypertension (DASH) trial, where
a diet incorporating increased fruit and vegetableintake produced substantially lower NEAP than the
typical American diet [47].
The usual diet consumed in the Western world is
quite different from that which our ancestors ate. Ances-
tral human diets were largely plant-based, and were
characterized by much lower levels of refined carbohy-
drates and sodium, and much higher levels of fiber and
potassium, than contemporary diets [49,50]. Sebastian
et al. estimated the net acid load from retrojected
ancestral pre-agricultural diets and compared it with con-
temporary diets [51]. They found that 87% of 159 retro-
jected pre-agricultural diets were net base-producing
with a mean NEAP of −88 mEq per day, compared
with +48 mEq per day for the average American diet.
Similarly, Strohle et al. examined the dietary net acid
load for 229 worldwide historically-studied hunter-
gatherer societies, and confirmed that the NEAP be-
came progressively more positive as the dietary plant-
to-animal ratio declined [52]. The historical shift from
negative to positive NEAP, or from net base-producing
to acid-producing, is thought due to the displacement
of high-bicarbonate-yielding plant foods in the ances-
tral diet by cereal grains and energy-dense, nutrition-
poor foods in the contemporary diet. It has been
postulated that on an evolutionary scale this change
has occurred rapidly, in a time span too brief for ad-
equate genetic adaptation [53-55]. The resultant mis-
match between the modern Western diet and a core
metabolic machinery that was selected for 50,000 to
100,000 years ago may therefore contribute to chronic
disease [56].
The high dietary acid load of contemporary diets could
impair kidney function by inducing metabolic acidosis
or even subclinical acid retention. In rats, acid loading
increased blood and renal cortical acid content mea-
sured by microdialysis, consistent with net acid retention
[57]. Despite no difference in blood pH or serum bicar-
bonate, rats with reduced nephron mass had higher
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ary acid accelerated GFR decline, which was ameliorated
by dietary alkali [58]. The decline in GFR caused by diet-
ary acid could be mediated by increased kidney ET and
aldosterone production [45,59] (Figure 1).
In humans, higher NEAP has been associated with
lower serum bicarbonate in persons with kidney disease
and in the general population [60,61]. Furthermore, this
association is strongest among those with more advanced
CKD and among middle-aged and older individuals, po-
pulations in whom the capacity to excrete an acid load is
relatively impaired [60,61]. Among 632 participants from
the AASK cohort study, higher NEAP was associated with
a faster decline in GFR over a median follow up of
3.2 years [62]. Thus, animal studies and epidemiologic
data link dietary acid load with the pathogenesis of pro-
gressive CKD.
Treatment
Several single-center clinical studies have examined the
effect of alkali therapy on the progression of kidney dis-
ease. In a 2-year, open-label, randomized trial, 134 pa-
tients with CKD stage 4 and serum bicarbonate levels of
16 to 20 mEq/L were assigned to receive oral sodium bi-
carbonate or to continue routine care [63]. Sodium bi-
carbonate was provided as 600 mg tablets dosed thrice
daily and increased as necessary to maintain bicarbonate
levels ≥23 mEq/L. Compared with the control group,
bicarbonate-supplemented patients experienced a slower
decline in creatinine clearance (5.93 vs. 1.88 mL/min/
1.73 m2; p < 0.0001) and fewer developed ESRD. This
was followed by another prospective interventional study
of 59 patients with a clinical diagnosis of hypertensive
nephropathy, all treated with regimens including an
angiotensin-converting enzyme (ACE) inhibitor, who
had an eGFR 20–59 mL/min/1.73 m2 and a serum bicar-
bonate <22 mEq/L [64]. Thirty patients prescribed so-
dium citrate were compared with the remaining 29
patients who were unable or unwilling to take sodium
citrate or bicarbonate. After 24 months, patients taking
sodium citrate had lesser eGFR decline and significantly
lower urinary ET-1 excretion and tubulo-interstitial in-
jury, as measured by urinary N-acetyl-β-D-glucosamini-
dase (NAG). In a second study by the same group, 120
patients with hypertensive nephropathy and CKD stage
2, all taking ACE inhibitors, were randomized in a
blinded fashion to receive 0.5 mEq/kg/day sodium bicar-
bonate, sodium chloride, or matching placebo. After
5 years, the rate of eGFR decline was slowest in the pa-
tients randomized to sodium bicarbonate, and they had
lower urine ET-1 and NAG compared with the other
groups [65]. Of note, the mean serum bicarbonate at
study entry among these 120 participants was 26.2 mEq/
L, well within the normal range.More recently, dietary modification has been examined
by Goraya and colleagues [66,67]. In patients with CKD
stage 2 due to hypertensive nephropathy, 30 days of
increased fruit and vegetable consumption produced
similar reductions in urinary NAG and albuminuria as
did oral sodium bicarbonate [66]. Similar results were
found in 71 patients with stage 4 CKD and serum bicar-
bonate <22 mEq/L who were randomized to 1 year of
sodium bicarbonate at 1.0 mEq/kg per day or increased
fruits and vegetables to reduce dietary acid by half [67].
The serum bicarbonate increased with the dietary interven-
tion, although less than in the bicarbonate group, whose al-
kali dose would be expected to nearly completely neutralize
the dietary acid load. The aforementioned markers of kid-
ney injury declined similarly in the 2 groups. It is encour-
aging that there were no complications from hyperkalemia,
but it should be noted that only patients with plasma
K+ ≤4.6 mEq/L were enrolled in the study.
Thus, accumulating evidence suggests that treatment
of chronic metabolic acidosis could slow the progression
of CKD. However, the evidence base is not yet definitive.
A systemic review was performed examining the pub-
lished literature regarding alkali therapy through July
2011 [68]. The authors concluded that although oral alkali
might afford a long-term benefit in slowing the progression
of CKD, differences in study protocols and small sample
sizes precluded definitive conclusions. Additional, more
nuanced questions also remain unanswered. If alkali
therapy does retard progression, what serum bicar-
bonate level should be targeted? Is there a risk to over-
correction of acidosis? Higher serum bicarbonate was
associated with increased risk of congestive heart failure
in the CRIC study [14], but to date interventional stud-
ies have not demonstrated significant metabolic alkal-
osis or fluid overload with even high-dose alkali. Is
serum bicarbonate even the right target, given evidence
of acid retention and deleterious effects within the nor-
mal range of serum bicarbonate? To what extent should
dietary interventions to reduce the dietary acid load be
employed in lieu of, or in addition to, oral alkali? There
are 3 ongoing randomized controlled trials of alkali
therapy in patients with CKD that have the potential to
answer some of these questions and to impact clinical prac-
tice (NCT01640119 [69]; NCT01452412 [70]; EUDRACT
Number 2012-001824-36 [71]). A summary of these trials
is provided in Table 2. Several smaller studies are exa-
mining other effects of base, including changes in uri-
nary TGF-β1 (NCT01574157), vascular endothelial function
(NCT02031770), and its role in sickle cell disease
(NCT01894594).
Conclusion
Patients with CKD develop metabolic acidosis due to re-
duced kidney mass and defects in renal acid excretion.
Table 2 Summary of on-going randomized clinical trials of alkali therapy in patients with chronic kidney disease
Title Correction of Metabolic Acidosis
with Use of Bicarbonate in
Chronic Renal Insufficiency
(NCT01640119) [69]
Alkali Therapy in Chronic Kidney
Disease (NCT01452412) [70]^
Oral Sodium Bicarbonate Supplementation
in Patients with Chronic Metabolic Acidosis








CKD stage Stage 3b & 4 Stage 3 & 4 Stage 3 & 4
Serum bicarbonate
levels at randomization
≥18 mEq/L 20-26 mEq/L <21 mEq/L
Study design Randomized, open label Randomized, placebo-controlled,
double blind
Randomized, open label
Intervention Bicarbonate administration to
keep bicarbonate levels between
24–28 mEq/L
Sodium bicarbonate 0.4 mEq / kg
ideal body weight per day
Sodium bicarbonate with target bicarbonate
levels of 24 ± 1 mEq/L
Control No intervention, partial correction if
bicarbonate <18 mEq/L (up to
22 mEq/L)
Placebo Rescue therapy of sodium bicarbonate with
target bicarbonate level of 20 ± 1 mEq/L
Locations Multiple centers in Italy 2 centers in the United States
(Bronx, NY and Cleveland, OH)
Single center in Vienna, Austria
Follow up length 36 months 24 months 24 months
Primary outcome Doubling of Cr HOMA-IR, sit to stand to sit speed,
DEXA of wrist, urinary NGAL & KIM-1




All-cause death, start of dialysis Glucose disposal rate by euglycemic
hyperinsulinemic clamp, hand-grip
strength, serum calcium, phosphate,
1,25-dihydroxyvitamin D, PTH, Cr,
cystatin C, urinary albumin/Cr ratio,
urinary cystatin
Death, need for renal replacement therapy,
change in markers of bone metabolism
Abbreviations: CKD, chronic kidney disease; Cr, creatinine; HOMA-IR, homeostasis model assessment-estimated insulin resistance; DEXA, dual energy X-ray
absorptiometry; NGAL, urinary neutrophil gelatinase-associated lipocalin; KIM-1, kidney injury molecule-1; PTH, parathyroid hormone; eGFR, estimated glomerular
filtrate rate; MDRD, modification of diet in renal disease; NY, New York; OH, Ohio.
^Our institution is one of the centers for the study (NCT01452412) and one of us (MKA) is a co-investigator. The information presented is updated
from clinicaltrials.gov.
#Recruitment was planned to start in October 2013.
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http://www.biomedcentral.com/1471-2369/15/55Chronic metabolic acidosis is a common complication
of CKD and appears to contribute to the progression of
kidney disease. High dietary acid intake has also been
demonstrated to worsen kidney function by induction of
metabolic acidosis and/or subclinical acid retention. The
factors that have been implicated in this effect of acidosis
on CKD progression include ammonia-induced activation
of the alternative complement system, as well as increased
endothelin and aldosterone production. Existing evidence
from clinical trials suggests that alkali therapy could retard
the progression of CKD. Increased fruit and vegetable
consumption appears to be a reasonable alternative to al-
kali therapy for patients with mild metabolic acidosis and
without hyperkalemia. However, definitive evidence is
lacking for optimal evidence-based practice guidelines.
Ongoing trials will hopefully facilitate more evidence-
based treatment of metabolic acidosis in the future.Competing interests
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